| Year |
Citation |
Score |
| 2024 |
Liu S, Daley EJ, Tran LM, Yu Z, Reyes M, Dean T, Khatri A, Levine PM, Balana AT, Pratt MR, Jüppner H, Gellman SH, Gardella TJ. Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants. Journal of the American Chemical Society. PMID 38417010 DOI: 10.1021/jacs.3c09694 |
0.539 |
|
| 2022 |
Levine PM, Craven TW, Li X, Balana AT, Bird GH, Godes M, Salveson PJ, Erickson PW, Lamb M, Ahlrichs M, Murphy M, Ogohara C, Said MY, Walensky LD, Pratt MR, et al. Generation of Potent and Stable GLP-1 Analogues Via "Serine Ligation". Acs Chemical Biology. PMID 35319882 DOI: 10.1021/acschembio.2c00075 |
0.716 |
|
| 2021 |
Balana AT, Levine PM, Craven TW, Mukherjee S, Pedowitz NJ, Moon SP, Takahashi TT, Becker CFW, Baker D, Pratt MR. O-GlcNAc modification of small heat shock proteins enhances their anti-amyloid chaperone activity. Nature Chemistry. PMID 33723378 DOI: 10.1038/s41557-021-00648-8 |
0.691 |
|
| 2019 |
Levine PM, Balana AJ, Sturchler E, Koole C, Noda H, Zarzycka B, Daley EJ, Truong TT, Katritch V, Gardella TJ, Wootten D, Sexton PM, McDonald P, Pratt MR. O-GlcNAc engineering of GPCR peptide-agonists improves their stability and in vivo activity. Journal of the American Chemical Society. PMID 31418572 DOI: 10.1021/Jacs.9B05365 |
0.686 |
|
| 2019 |
Levine PM, Galesic A, Balana AT, Mahul-Mellier AL, Navarro MX, De Leon CA, Lashuel HA, Pratt MR. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 30651314 DOI: 10.1073/Pnas.1808845116 |
0.754 |
|
| 2018 |
Levine PM, Pratt MR. Revolutionizing Our Understanding of Amyloidogenic Proteins by Cryo-Electron Microscopy. Biochemistry. PMID 29323876 DOI: 10.1021/Acs.Biochem.7B01084 |
0.51 |
|
| 2017 |
De Leon CA, Levine PM, Craven TW, Pratt MR. The sulfur-linked analog of O-GlcNAc (S-GlcNAc) is an enzymatically stable and a reasonable structural-surrogate for O-GlcNAc at the peptide and protein levels. Biochemistry. PMID 28627871 DOI: 10.1021/Acs.Biochem.7B00268 |
0.754 |
|
| 2017 |
Levine PM, De Leon CA, Galesic A, Balana A, Marotta NP, Lewis YE, Pratt MR. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein. Bioorganic & Medicinal Chemistry. PMID 28487126 DOI: 10.1016/J.Bmc.2017.04.038 |
0.676 |
|
| 2017 |
Lewis YE, Galesic A, Levine PM, De Leon CA, Lamiri N, Brennan CK, Pratt MR. O-GlcNAcylation of α-synuclein at serine 87 reduces aggregation without affecting membrane binding. Acs Chemical Biology. PMID 28195695 DOI: 10.1021/Acschembio.7B00113 |
0.822 |
|
| Show low-probability matches. |